Mirati Therapeutics (MRTX) Offers Data from on Glesatinib and Sitravatinib Clinical Trials
Tweet Send to a Friend
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced data from two ongoing clinical programs, including the Phase 1b and Phase 2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
